The Financial Comet
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

The Financial Comet

Business

FDA officially authorizes Zyn nicotine pouches for sale following health review

by admin January 23, 2025
January 23, 2025
FDA officially authorizes Zyn nicotine pouches for sale following health review

The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an ‘extensive scientific review’ about their safety.

In a release Thursday, the agency said it had found that the popular pouches posed lower risk of cancer and other serious health conditions compared with cigarettes, as well as in relation to other smokeless tobacco products.

The agency also found that the pouches even had the potential to benefit cigarette smokers amid evidence that they can get them to quit.

‘The data show that these nicotine pouch products meet that bar by benefiting adults who use cigarettes and/or smokeless tobacco products and completely switch to these products,” Matthew Farrelly, director of the office of science in the FDA’s Center for Tobacco Products, said in a statement. 

Zyn use has exploded in recent years in the wake of a viral online meme trend, even prompting a shortage last year. Yet the product had been operating in a legal gray area while it underwent official FDA review about its health effects and uptake among young users.

To that latter point, the FDA found that, so far, Zyn use among youths appeared to be relatively low, though it was continuing to monitor the trend.

A spokesperson for Philip Morris International Inc., which owns the U.S. rights to Zyn, did not immediately respond to a request for comment.

Swedish Match, the developer of Zyn, said in a statement, “The FDA’s authorization of all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. is an important step to protect the public health by providing better alternatives to cigarettes and other traditional tobacco products for adults 21+.”

The Campaign for Tobacco-Free Kids slammed the FDA’s decision in a separate statement.

‘The FDA today has set a dangerous precedent that puts the nation’s kids at risk by authorizing the sale of 20 Zyn nicotine pouch products with flavors that clearly appeal to kids, including chill, citrus, cool mint and peppermint,’ it said.

‘The FDA’s decision is deeply troubling given the extensive scientific evidence that flavored tobacco products appeal to kids and the fact that nicotine pouches were the only category of tobacco product that saw an increase in youth use last year. The FDA is sanctioning a flavored tobacco product that is already increasing in popularity with kids and repeating the mistakes it made with Juul that resulted in the youth e-cigarette epidemic.’

In the release, the FDA emphasized that its findings about Zyn did not mean the products are ultimately safe or “FDA approved.”

‘There is no safe tobacco product,’ the agency said. ‘Youth should not use tobacco products and adults who do not use tobacco products should not start.’

This post appeared first on NBC NEWS

previous post
With Trump digital coins, billions of dollars — and crypto’s credibility — are at stake
next post
VRIC 2025: Experts Tout Hard Assets, Energy as Sure Bets Amid Uncertainty

Related Posts

Southern California Edison acknowledges videos suggest link between...

February 8, 2025

Consumers are not lovin’ it: McDonald’s has its...

May 2, 2025

Fanatics will host a skills challenge between fans...

May 22, 2025

Nvidia loses nearly $600 billion in market value...

January 28, 2025

UnitedHealth CEO suddenly steps down for ‘personal reasons’

May 14, 2025

The trucking industry hits the brakes with tariffs...

April 25, 2025

DeepSeek hit with large-scale cyberattack, says it’s limiting...

January 28, 2025

Walgreens doubles down on prescription-filling robots to cut...

May 14, 2025

Treasury ends enforcement of business ownership database meant...

March 4, 2025

Buffett denies rumors after Trump shares wild claim...

April 6, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 2

      DeepSeek hit with large-scale cyberattack, says it’s limiting registrations

      January 28, 2025
    • 3

      Bank of America CEO says financial industry will jump into crypto payments if regulators allow it

      January 23, 2025
    • 4

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • 5

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 27, 2025
    • 6

      UnitedHealthcare taps company veteran Tim Noel as new CEO following Brian Thompson killing

      January 27, 2025
    • 7

      Lara Trump to host weekend show on Fox News

      February 7, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: thefinancialcomet.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 thefinancialcomet.com | All Rights Reserved